Logo

Gilead, Eisai and EA Pharma’s Jyseleca (filgotinib) Receive the MHLW’s Approval for the Treatment of Ulcerative Colitis

Share this

Gilead, Eisai and EA Pharma’s Jyseleca (filgotinib) Receive the MHLW’s Approval for the Treatment of Ulcerative Colitis

Shots:

  • The approval was based on the P-IIb/III (SELECTION) study evaluating Jyseleca (200mg) in patients with mod. to sev. active UC who had an inadequate response or were intolerant to conventional therapy or a biologic agent
  • The study results showed that the therapy was well-tolerated & efficacious as induction & maintenance therapy & no new safety results were reported
  • Gilead will obtain the marketing authorization of Jyseleca in Japan & will be responsible for product supply. Eisai will lead the product distribution & will commercialize the product in collaboration with EA Pharma. In Sept 2020, the therapy has been approved in Japan for RA including the prevention of structural joint damage

Ref: Globe Newswire | Image: Gilead

Click here to­ read the full press release 

Senior Editor

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions